• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Boehringer acquires AMAL Therapeutics for $366m pharmaceutical-technology
    July 17, 2019
    Boehringer Ingelheim has expanded its cancer immunology portfolio with the acquisition of Swiss biotechnology firm AMAL Therapeutics for up to €325m ($366m).
  • AMAL Therapeutics Finalises €29 Million (CHF 33.2 Million) Series B Round b3cnewswire
    November 12, 2018
    The Company will use the funds to progress its lead vaccine (ATP128) toward clinical development and proof-of-concept in colorectal cancer, a leading cause of mortality and a significant market opportunity (€9.6 billion by 2025). The clinical trial is exp

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service